86 related articles for article (PubMed ID: 18825844)
21. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene.
Syampurnawati M; Tatsumi E; Furuta K; Hayashi Y
Leuk Res; 2007 Jun; 31(6):877. PubMed ID: 16949153
[No Abstract] [Full Text] [Related]
22. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
23. Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome.
Green C; Linch DC; Gale RE
Br J Haematol; 2008 Jul; 142(3):423-6. PubMed ID: 18537976
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.
Löwenberg B
N Engl J Med; 2008 May; 358(18):1960-2. PubMed ID: 18450608
[No Abstract] [Full Text] [Related]
25. Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review.
Tosić N; Stojiljković M; Colović N; Colović M; Pavlović S
Cancer Genet Cytogenet; 2009 Sep; 193(2):98-103. PubMed ID: 19665070
[TBL] [Abstract][Full Text] [Related]
26. Molecular classification of acute myeloid leukemia: are we there yet?
Radich JP
J Clin Oncol; 2008 Oct; 26(28):4539-41. PubMed ID: 18559871
[No Abstract] [Full Text] [Related]
27. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
[TBL] [Abstract][Full Text] [Related]
28. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells.
Oveland E; Gjertsen BT; Wergeland L; Selheim F; Fladmark KE; Hovland R
Leuk Res; 2009 Feb; 33(2):276-87. PubMed ID: 18691757
[TBL] [Abstract][Full Text] [Related]
29. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of acute myeloid leukemia.
Döhner K; Döhner H
Haematologica; 2008 Jul; 93(7):976-82. PubMed ID: 18591623
[No Abstract] [Full Text] [Related]
31. Comparing apples and oranges in normal karyotype acute myeloid leukemia.
Medeiros BC
J Clin Oncol; 2009 Jan; 27(3):474; author reply 474-6. PubMed ID: 19075259
[No Abstract] [Full Text] [Related]
32. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.
Riccioni R; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Ottone T; Foà R; Testa U
Br J Haematol; 2009 Feb; 144(3):376-87. PubMed ID: 19036083
[TBL] [Abstract][Full Text] [Related]
33. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
[TBL] [Abstract][Full Text] [Related]
34. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
35. [Acute myeloid leukemia].
Watanabe R
Rinsho Ketsueki; 2009 Mar; 50(3):154-9. PubMed ID: 19352081
[No Abstract] [Full Text] [Related]
36. Clinical progress in acute myeloid leukemia. Preface.
Rowe JM
Best Pract Res Clin Haematol; 2008 Dec; 21(4):597-9. PubMed ID: 19041598
[No Abstract] [Full Text] [Related]
37.
Loo S; Wei AH
Haematologica; 2022 Apr; 107(4):783-784. PubMed ID: 34348456
[No Abstract] [Full Text] [Related]
38. Gene expression profiling in acute myeloid leukaemia (AML).
Bacher U; Kohlmann A; Haferlach C; Haferlach T
Best Pract Res Clin Haematol; 2009 Jun; 22(2):169-80. PubMed ID: 19698926
[TBL] [Abstract][Full Text] [Related]
39. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia.
Schlenk RF; Döhner K
Curr Opin Hematol; 2009 Mar; 16(2):98-104. PubMed ID: 19468271
[TBL] [Abstract][Full Text] [Related]
40. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
